Search Prime Grants

U01HL134812

Cooperative Agreement

Overview

Grant Description
Stem cells for therapeutics discovery in genetic blood disorders.
Awardee
Children's Hospital Corporation
Funding Goals
THE DIVISION OF BLOOD DISEASES AND RESOURCES SUPPORTS RESEARCH AND RESEARCH TRAINING ON THE PATHOPHYSIOLOGY, DIAGNOSIS, TREATMENT, AND PREVENTION OF NON-MALIGNANT BLOOD DISEASES, INCLUDING ANEMIAS, SICKLE CELL DISEASE, THALASSEMIA, LEUKOCYTE BIOLOGY, PRE-MALIGNANT PROCESSES SUCH AS MYELODYSPLASIA AND MYELOPROLIFERATIVE DISORDERS, HEMOPHILIA AND OTHER ABNORMALITIES OF HEMOSTASIS AND THROMBOSIS, AND IMMUNE DYSFUNCTION. FUNDING ENCOMPASSES A BROAD SPECTRUM OF HEMATOLOGIC INQUIRY, RANGING FROM STEM CELL BIOLOGY TO MEDICAL MANAGEMENT OF BLOOD DISEASES AND TO ASSURING THE ADEQUACY AND SAFETY OF THE NATION'S BLOOD SUPPLY. PROGRAMS ALSO SUPPORT THE DEVELOPMENT OF NOVEL CELL-BASED THERAPIES TO BRING THE EXPERTISE OF TRANSFUSION MEDICINE AND STEM CELL TECHNOLOGY TO THE REPAIR AND REGENERATION OF HUMAN TISSUES AND ORGANS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.
Grant Program (CFDA)
93.837 - Cardiovascular Diseases Research
Awarding / Funding Agency
National Heart Lung and Blood Institute (NHLBI) [HHS - NIH]
Place of Performance
Massachusetts United States
Geographic Scope
State-Wide
Related Opportunity
NHLBI Progenitor Cell Translational Consortium (U01) (RFA-HL-16-021)
Analysis Notes
Amendment Since initial award the End Date has been extended from 05/31/23 to 05/31/25 and the total obligations have increased 690% from $1,044,680 to $8,256,108.
Children's Hospital Corporation was awarded Stem cells for therapeutics discovery in genetic blood disorders Cooperative Agreement U01HL134812 worth $8,256,108 from National Heart Lung and Blood Institute in September 2016 with work to be completed primarily in Massachusetts United States. The grant has a duration of 8 years 8 months and was awarded through assistance program 93.837 Cardiovascular Diseases Research. The Cooperative Agreement was awarded through grant opportunity NHLBI Progenitor Cell Translational Consortium (U01).

Status
(Complete)

Last Modified 11/20/25

Period of Performance
9/23/16
Start Date
5/31/25
End Date
100% Complete

Funding Split
$8.3M
Federal Obligation
$0.0
Non-Federal Obligation
$8.3M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to U01HL134812

Subgrant Awards

Disclosed subgrants for U01HL134812

Transaction History

Modifications to U01HL134812

Additional Detail

Award ID FAIN
U01HL134812
SAI Number
U01HL134812-991806607
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Funding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Awardee UEI
Z1L9F1MM1RY3
Awardee CAGE
2H173
Performance District
MA-90
Senators
Edward Markey
Elizabeth Warren

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Heart, Lung, and Blood Institute, National Institutes of Health, Health and Human Services (075-0872) Health research and training Grants, subsidies, and contributions (41.0) $9,534,380 100%
Modified: 11/20/25